Alzheimer’s disease (AD) is considered a secondary tauopathy, as beta amyloid (Aβ) plaque deposition precedes tau accumulation (Cody et al., 2024). The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.